Also trades as: PFE.TO (TSX) · $vol 1M · PFE.F (FSX) · $vol 1M · PFE.DE (XETRA) · $vol 1M · PFE.NE (NEO) · $vol 1M · PFE.BA (BUE) · $vol 0M
PFE NYSE
Pfizer Inc.
1W: +1.2%
1M: +3.9%
3M: +18.0%
YTD: +20.3%
1Y: +22.9%
3Y: +10.2%
5Y: -10.7%
$29.73
-0.06 (-0.20%)
Weekly Expected Move ±2.9%
$28
$29
$30
$31
$32
Credit Risk of going bust: lower than 82% of companies Debt: 27.1% of company value Bonds: $1.15B held by 485 funds, 62 bp over Treasuries → details ▾
Of US companies ranked in the safest four tenths, about 1 in 3,500 filed for bankruptcy within a year (2020-2025).
If the stock fell to about $0.54 (down 98%), Pfizer Inc. would be worth roughly what it owes.
Total debt $63.19B against a stock market value of $169.79B.
Distance to default 10.27 (Merton model): prices to 2026-10-26, balance sheet 2026-06-28, debt counted $32.95B (short-term plus half of long-term), stock volatility 21.2%; Altman Z 2.14. A ranking and a back-test, not a forecast.
Bond figures are fund-reported marks (SEC N-PORT) as of Jul 2026. How these are computed.
If the stock fell to about $0.54 (down 98%), Pfizer Inc. would be worth roughly what it owes.
Total debt $63.19B against a stock market value of $169.79B.
Distance to default 10.27 (Merton model): prices to 2026-10-26, balance sheet 2026-06-28, debt counted $32.95B (short-term plus half of long-term), stock volatility 21.2%; Altman Z 2.14. A ranking and a back-test, not a forecast.
Bond figures are fund-reported marks (SEC N-PORT) as of Jul 2026. How these are computed.
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Supply Chain Overview
24 relationships3
As Filer
counterparties named
21
As Counterparty
mentioned by others
2
Rel. Types
2021-07-01
Earliest Filing
2026-02-24
Latest Filing
target: 2
investor: 1
Counterparties (Filed by PFE)
3 relationshipsCompanies named in PFE's SEC 8-K filings as business counterparties.
| Counterparty | Ticker | Relationship | Summary | Filing Date | SEC |
|---|---|---|---|---|---|
| Seagen Inc. | SGEN | target | Target company in the merger with Pfizer Inc. | 2023-12-14 | View |
| Seagen Inc. | SGEN | target | Target company in a merger agreement with Pfizer Inc. | 2023-03-13 | View |
| Baker Bros. Advisors LP | — | investor | Financial advisor and voting agreement signatory representing stockholders. | 2023-03-13 | View |
Mentioned As Counterparty
21 mentionsOther companies that named PFE in their SEC 8-K filings.
| Filed By | Relationship | Summary | Filing Date | SEC |
|---|---|---|---|---|
| BEAM Beam Therapeutics Inc. | partner | Partner entering an exclusive worldwide license and potential co-development agreement for a liver-targeted development | 2026-02-24 | View |
| XOMAP XOMA Royalty Corp | partner | Partner holding an outlicensed agreement for the EGFRd2 (PF-8046052) legacy asset. | 2026-02-02 | View |
| NVAX NOVAVAX INC | partner | Novavax entered into a License and Option Agreement for Pfizer to research, develop, and commercialize the Matrix-MTM ad | 2026-01-20 | View |
| LONA Athira Pharma, Inc. | partner | Original collaborator in discovery of lasofoxifene | 2025-12-18 | View |
| LONA Athira Pharma, Inc. | partner | Original discoverer and developer of lasofoxifene | 2025-12-18 | View |
| ITRM Iterum Therapeutics plc | partner | Licensee and counterparty to the amended promissory note and letter agreement regarding the deferred regulatory mileston | 2025-05-19 | View |
| ROIV Roivant Sciences Ltd. | target | Acquired Telavant Holdings, Inc. for approximately $7.1 billion in cash. | 2023-12-14 | View |
| ARVN ARVINAS, INC. | partner | Collaboration partner mentioned in forward-looking statements. | 2023-11-27 | View |
| RNTX AILERON THERAPEUTICS INC | partner | Company that acquired ReViral Ltd. | 2023-10-31 | View |
| CRBU Caribou Biosciences, Inc. | investor | Caribou Biosciences issued and sold 4,690,431 shares of common stock to Pfizer in a private placement for approximately | 2023-07-06 | View |
| IDYA IDEAYA Biosciences, Inc. | partner | Clinical trial collaboration and supply partner providing crizotinib for IDEAYA's Phase 1/2 and planned Phase 2/3 trials | 2023-05-16 | View |
| PYXS Pyxis Oncology, Inc. | licensee | Pyxis Oncology entered into an amended and restated license agreement to obtain exclusive worldwide rights to Pfizer's F | 2022-10-07 | View |
| CDXS CODEXIS, INC. | supplier | Agreement for Codexis to supply proprietary enzyme CDX-616 for use in manufacturing Pfizer's PAXLOVID product. | 2022-07-14 | View |
| VERA Vera Therapeutics, Inc. | partner | Parent company of Amplyx Pharmaceuticals, Inc. | 2021-12-17 | View |
| EXAS EXACT SCIENCES CORP | partner | Amendment to promotion agreement ending Pfizer's promotion of Cologuard and establishing payment terms. | 2021-11-29 | View |
| CRDF Cardiff Oncology, Inc. | investor | Cardiff Oncology sold common stock to Pfizer in a registered direct offering. | 2021-11-18 | View |
| LPCN Lipocine Inc. | partner | Strategic alliance partner mentioned in Antares Pharma portfolio | 2021-10-18 | View |
| VYGR Voyager Therapeutics, Inc. | partner | Voyager Therapeutics granted Pfizer options to receive an exclusive license to novel capsids for developing and commerci | 2021-10-06 | View |
| MRVI MARAVAI LIFESCIENCES HOLDINGS, INC. | supplier | Counterparty to the amended supply agreement | 2021-09-03 | View |
| ARVN ARVINAS, INC. | partner | Entered into a collaboration agreement for co-exclusive rights to develop and commercialize ARV-471, plus a stock purcha | 2021-07-22 | View |
| SPRO Spero Therapeutics, Inc. | partner | Licensee and investor in a $40 million stock purchase and product development agreement. | 2021-07-01 | View |
Recent 8-K Filings (20)
| Filing Date | Description | Type | SEC |
|---|---|---|---|
| 2026-08-04 | Earnings Release; Exhibits | View | |
| 2026-06-18 | Officer/Director Change; Exhibits | View | |
| 2026-06-18 | Regulation FD | View | |
| 2026-05-05 | Earnings Release; Exhibits | View | |
| 2026-04-27 | Shareholder Vote | View | |
| 2026-02-03 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-12-16 | Regulation FD Disclosure; Financial Statements and Exhibits | View | |
| 2025-11-21 | Other Events; Financial Statements and Exhibits | View | |
| 2025-11-13 | Other Events | View | |
| 2025-11-04 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-08-05 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-05-19 | Other Events; Financial Statements and Exhibits | View | |
| 2025-04-29 | Results of Operations and Financial Condition; Costs Associated with Exit or Disposal Activities; Fi | View | |
| 2025-04-28 | Submission of Matters to a Vote of Security Holders | View | |
| 2025-02-04 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2024-12-17 | Regulation FD Disclosure; Financial Statements and Exhibits | View | |
| 2024-10-29 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2024-10-15 | Departure/Election of Directors; Appointment of Officers; Financial Statements and Exhibits | View | |
| 2024-07-30 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2024-07-26 | Departure/Election of Directors; Appointment of Officers; Other Events; Financial Statements and Exh | View |
Data extracted from SEC EDGAR 8-K filings using NLP. Relationships are as disclosed in filing text.
Covers 2021–2026. View on SEC EDGAR